[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR056076A1 - PROFILACTIC OR THERAPEUTIC AGENT FOR SOUND DISORDER - Google Patents

PROFILACTIC OR THERAPEUTIC AGENT FOR SOUND DISORDER

Info

Publication number
AR056076A1
AR056076A1 ARP060104043A ARP060104043A AR056076A1 AR 056076 A1 AR056076 A1 AR 056076A1 AR P060104043 A ARP060104043 A AR P060104043A AR P060104043 A ARP060104043 A AR P060104043A AR 056076 A1 AR056076 A1 AR 056076A1
Authority
AR
Argentina
Prior art keywords
sleep
therapeutic agent
profilactic
disorder
sound disorder
Prior art date
Application number
ARP060104043A
Other languages
Spanish (es)
Inventor
K Hirai
M Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37888821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056076(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP2006117524A external-priority patent/JP2008303146A/en
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR056076A1 publication Critical patent/AR056076A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La combinacion de una o más drogas seleccionadas del grupo que consiste de antidepresivos sedantes y antihistaminas con (S)-N-[2-(1,6,7,8-tetrahidro-2H-indeno[5,4-b]furan-8-il)etil]propionamida, se provee un agente profiláctico o terapéutico para desorden de sueno que induce el sueno natural, acorta la latencia de sueno, aumenta el sueno profundo, es excelente para mantener el sueno, y ejerce el control para lograr una duracion de sueno apropiada.The combination of one or more drugs selected from the group consisting of sedative antidepressants and antihistamines with (S) -N- [2- (1,6,7,8-tetrahydro-2H-indene [5,4-b] furan- 8-yl) ethyl] propionamide, a prophylactic or therapeutic agent for sleep disorder is provided that induces natural sleep, shortens sleep latency, increases deep sleep, is excellent for maintaining sleep, and exerts control to achieve appropriate sleep duration.

ARP060104043A 2005-09-20 2006-09-15 PROFILACTIC OR THERAPEUTIC AGENT FOR SOUND DISORDER AR056076A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005272260 2005-09-20
JP2006117524A JP2008303146A (en) 2005-09-20 2006-04-21 Sleep disorder-preventing or treating agengt

Publications (1)

Publication Number Publication Date
AR056076A1 true AR056076A1 (en) 2007-09-19

Family

ID=37888821

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104043A AR056076A1 (en) 2005-09-20 2006-09-15 PROFILACTIC OR THERAPEUTIC AGENT FOR SOUND DISORDER

Country Status (2)

Country Link
AR (1) AR056076A1 (en)
WO (1) WO2007034778A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997488A4 (en) * 2006-03-20 2010-04-21 Takeda Pharmaceutical Agent for prevention/treatment of irritable bowel syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2943247B2 (en) * 1990-05-31 1999-08-30 藤沢薬品工業株式会社 Hypnosis / Sedative
IT1251544B (en) * 1991-05-13 1995-05-17 Gabriele Biella PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE
JP2884153B2 (en) * 1996-03-08 1999-04-19 武田薬品工業株式会社 Tricyclic compound, its production method and agent
JP3509637B2 (en) * 1998-06-09 2004-03-22 武田薬品工業株式会社 Sleep disorder prevention / treatment agent
EP1283038B1 (en) * 2000-05-16 2008-09-03 Suntory Limited Compositions normalizing circadian rhythm
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
JP4780907B2 (en) * 2003-09-30 2011-09-28 小林製薬株式会社 Hypnotic composition

Also Published As

Publication number Publication date
WO2007034778A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
CL2008001268A1 (en) Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain.
DE60204966D1 (en) Use of cyclopamine for the manufacture of a medicament for the treatment of psoriasis
MX2009013989A (en) Combination therapy for depression.
CL2018001420A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof. (divisional application 201701853)
CL2011000916A1 (en) Use of a combination of an epoxy ketone peptide proteasome inhibitor or an acceptable pharmaceutical salt thereof, and one or more other therapeutic agents to treat cancer.
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
GT200600409A (en) USE OF AGOMELATIN TO OBTAIN PROPOSED MEDICINES FOR THE TREATMENT OF SLEEP DISORDERS IN THE DEPRESSED PATIENT.
EE200200107A (en) Use of a fast-acting selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction
UA84697C2 (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
CR8850A (en) COMPOSITION AND METHOD TO TREAT HEMORROIDS AND / OR ANO-RECTURAL DISORDERS
CL2009000980A1 (en) Use of (s) -n- (2- (1,6,8-tetrahydro-2h-inden [5,4-b] furan-8-yl) ethyl] propionamide in combination with one or more drugs selected from a group defined to prepare a drug useful for the prevention or treatment of depression or anxiety disorders (divisional application 749-2006).
ECSP10010464A (en) USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CR7271A (en) NEW MELATONIN-BASED PHARMACEUTICAL FORMULATIONS AND SIMILAR COMPOUNDS FOR USE IN SOUND DISORDERS
TW200626137A (en) Preventive or therapeutic agent for sleep disorder
AR056076A1 (en) PROFILACTIC OR THERAPEUTIC AGENT FOR SOUND DISORDER
ITMI20040954A1 (en) DERIVATIVES OF 3,6-DIAZABICICLO 3.1.I. HEPTANE WITH ANALGESIC ACTIVITY
AR045423A1 (en) COMBINATIONS OF ANALYTICS AND ANTIDEPRESSANTS
CR9074A (en) AGENT FOR THE PROPHYLAXIS OR TREATMENT OF METABOLIC SYNDROME
AR047716A1 (en) ANALEPTIC AND ANTIDEPRESSIVE COMBINATIONS
AR044675A1 (en) METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN A PATIENT WITH OVERWEIGHT
RU2007122391A (en) S-MIRTAZAPINE FOR TIDAL TREATMENT
ES2507517T3 (en) Prophylactic or therapeutic agent for attention deficit hyperactivity disorder
PE20020907A1 (en) COMBINATION OF TAXANE AND A CYCLINE-DEPENDENT KINASE
CR9376A (en) AGENT FOR THE PREVENTION OR TREATMENT OF THE DISORDER OF NIGHT CONDUCT ASSOCIATED WITH DEMENTIA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal